Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Collaboration between Labcorp and Epic drives meaningful operational efficiencies, streamlines lab ordering for clinicians and care teams, and improves access to diagnostic innovation for hospitals and health systems using Epic nationwide. This expanded collaboration with the nation's leading electronic health record (EHR) supporting hospitals and health systems.

According to Towards Healthcare, the U.S. central lab market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.58 billion in 2026 to approximately USD 5.19 billion by 2035, representing a compound annual growth rate (CAGR) of 8.08% from 2026 to 2035. Growth is driven by the shift towards biologic drugs, gene therapies, and complex drug compounds requires highly specialized assays that central labs are best equipped to deliver, reduce overhead, and streamline operations. These firms heavily outsource routine and specialized testing to specialized central labs.

Reducing Complexity and Expanding Access to Testing and Diagnostic Innovation

Integration with partners and leveraging Epic’s Aura, the expansion will reduce the time, cost, and ongoing maintenance typically required for lab interfaces. Availability of Invitae genetic tests through Aura, part of Labcorp’s diagnostic portfolio, will enable health systems will be able to access Labcorp’s full test menu and new tests as they are introduced directly within their existing Epic workflows.

Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp, by simplifying lab integrations and delivering our full test menu directly within Epic workflows, we are expanding access and building a strong foundation for continued innovation.

About Labcorp

Labcorp is a leading global life sciences and healthcare company and provide vital health answers by processing millions of routine tests, complex genetic analyses, and clinical trial data to support patients, doctors, and pharmaceutical companies worldwide.

Partners with biopharmaceutical and biotech companies to accelerate preclinical and clinical research, helping bring new vaccines and cancer-treating breakthroughs to market, and patients can access health insights through the Labcorp Patient Portal to easily schedule appointments, view test results, and estimate out-of-pocket costs at local collection sites.

A recent report by Towards Healthcare highlights that the U.S. central lab market is witnessing growth driven by genetic and biomarker services. Genetic testing is the fastest-growing opportunity due to a higher demand for gene-based therapies and oncology research, and opportunities lie in deploying AI, machine learning, and automation into lab processes to speed up diagnostic turnaround times